Biofrontera AG (LTS:0DOL) Other Stockholders Equity: €0.03 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DOL Biofrontera AG LTS:0DOL
16 GF Score
Price €2.27
GF Value €2.42
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG Other Stockholders Equity?

Biofrontera AG LTS:0DOL -5.81% 16 Other Stockholders Equity is €0.03 Mil as of Mar. 2026. GuruFocus rates LTS:0DOL with a GF Score™ of 16/100 and a GF Value™ of €2.42 (Fairly Valued). The stock has 4 warning signs investors should review.

Biofrontera AG's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €0.03 Mil.

Biofrontera AG's quarterly Other Stockholders Equity increased from Sep. 2025 (€0.03 Mil) to Dec. 2025 (€0.03 Mil) but then declined from Dec. 2025 (€0.03 Mil) to Mar. 2026 (€0.03 Mil).

Biofrontera AG's annual Other Stockholders Equity increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.02 Mil) and increased from Dec. 2024 (€0.02 Mil) to Dec. 2025 (€0.03 Mil).

Biofrontera AG Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Biofrontera AG's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG Other Stockholders Equity Chart

Biofrontera AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.02 0.03

Biofrontera AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.00 0.03 0.03 0.03
LTS:0DOL
16GF Score
Biofrontera AG LTS:0DOL
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera AG Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.03 Mil mean?
Biofrontera AG (LTS:0DOL) has a Other Stockholders Equity of €0.03 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Biofrontera AG and its competitors.
Is Biofrontera AG's Other Stockholders Equity too high?
Biofrontera AG's current Other Stockholders Equity is €0.03 Mil. Overall, Biofrontera AG has a GF Score™ of 16/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Other Stockholders Equity compare to ZTS and UTHR?
Biofrontera AG's Other Stockholders Equity of €0.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current Other Stockholders Equity is €0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (LTS:0DOL) is currently considered Fairly Valued. The stock's GF Value™ is €2.42, compared to a current price of €2.27 — trading 6.2% below its estimated fair value. The current Other Stockholders Equity is €0.03 Mil. Biofrontera AG's overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current Other Stockholders Equity is €0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of €2.27 is trading 6.2% below its estimated GF Value™ of €2.42. GuruFocus considers Biofrontera AG to be Fairly Valued.

Key valuation signals for LTS:0DOL:

  • Other Stockholders Equity: €0.03 Mil
  • GF Value™: €2.42 vs. price of €2.27 (6.2% below fair value)
  • GF Score™: 16/100 with 4 warning signs

No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges B8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
16GF Score

Get the complete analysis for LTS:0DOL

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.27
Price
€2.42
GF Value